Clinical Research Directory

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Willing and able to sign informed consent form * Willing and able to participate in baseline and serial audiometry exams * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) of 0 or 1 or Karnofsky score ≥ 70 * Histologically confirmed germ cell tumor (seminoma or non-seminoma) * Presence of metastatic disease (stage II or III) * Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy * Receiving first or second line cisplatin-based chemotherapy * Planned cumulative cisplatin dose of ≥ 300mg/m\^2 (including previous treatment) * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 * Platelets ≥ 100,000/mm\^3 * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement * Hemoglobin ≥ 9g/dL * NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement * Total bilirubin ≤ 1.5 X upper limit of normal (ULN) * Patients with known Gilbert disease who have serum bilirubin level \< 3 x ULN may be enrolled * Aspartate aminotransferase (AST) ≤ 3.0 x ULN * Alanine aminotransferase (ALT) ≤ 3.0 x ULN * Creatinine clearance of ≥ 60 mL/min per the Cockcroft-Gault formula or serum creatinine ≤ 1.5 x ULN * \* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 x ULN * If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants * \* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN * If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants * Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months after the last dose of cisplatin for injection Exclusion Criteria: * Any cisplatin-based therapies within 4 weeks prior to initiation of study treatment * If cisplatin infusion during study is planned to be longer than 6 hours, as Pedmark safety and efficacy has not been established when administered following longer cisplatin infusions * Chronic steroid use, defined as greater than prednisone 5 mg daily for longer than 21 days (steroids used as antiemetic during treatment is permitted) * Concurrent use of other ototoxic drugs other than cisplatin (loop diuretics, aminoglycosides, etc) * Patient must adhere to low sodium diet given other comorbidities * History of severe hypersensitivity to sodium thiosulfate or any components such as sulfites or thiols * Known symptomatic brain metastases, leptomeningeal carcinomatosis, or prior cranial irradiation * Deemed cisplatin ineligible due to poor performance status, cardiac dysfunction, renal insufficiency, or significant peripheral neuropathy * Greater than or equal to moderate hearing loss (HL) at baseline per World Health Organization (WHO) classification * Unstable cardiac disease as defined by one of the following: * Cardiac events such as myocardial infarction (MI) within the past 6 months * NYHA (New York Heart Association) heart failure class III-IV * Uncontrolled atrial fibrillation or hypertension * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)